Oncology Central

Overcoming immune system evasion by personalized immunotherapy


With the US FDA’s approval of the first cancer vaccine for prostate cancer [1] and immune checkpoint blockade therapy against CTLA-4 for melanoma [2], the complex interaction between antitumor immune responses and tumor immune evasion is being intensely scrutinized. Despite a number of exciting preclinical studies and clinical research, most novel immunotherapies have demonstrated limited efficacy in early-phase clinical trials. The reason for this is multifactorial.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.